<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130208</url>
  </required_header>
  <id_info>
    <org_study_id>KRX-101-301</org_study_id>
    <nct_id>NCT00130208</nct_id>
  </id_info>
  <brief_title>Effect of Sulodexide in Early Diabetic Nephropathy</brief_title>
  <official_title>The Collaborative Study Group Trial: The Effect of Sulodexide in Patients With Type 2 Diabetes and Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keryx Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Collaborative Study Group (CSG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Keryx Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether treatment with sulodexide is effective in
      reducing the level of urine albumin excretion in patients with early diabetic kidney disease
      expressed as microalbuminuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic nephropathy is an important cause of morbidity and mortality in patients with either
      type 1 or type 2 diabetes mellitus. The pathogenesis and natural history of diabetic
      nephropathy is characterized initially by microalbuminuria followed by a progressive decline
      in glomerular function. An emerging body of evidence supports the notion that glomerular
      capillary wall and mesangial alterations in diabetic nephropathy involve pathobiochemical
      alterations of glycoproteins in these structures. Evidence, in experimental animals rendered
      diabetic, reveals that the administration of heparin and other anionic glycoproteins (GAG)
      can effectively prevent the biochemical alterations which are responsible for albuminuria.
      Sulodexide, an orally active agent which does not have anticoagulant properties associated
      with its oral dose range, is comprised of three naturally occurring glycosaminoglycan (GAG)
      polysaccharide components isolated from porcine intestinal mucosa. Small clinical studies
      employing sulodexide, have shown that albuminuria is significantly diminished in patients
      with diabetic nephropathy, even when these patients are receiving angiotensin II receptor
      blockers (ARB) or angiotensin converting enzyme inhibitors (ACEI), agents already proven to
      reduce albuminuria and slow progressive diabetic nephropathy.

      This study is designed to evaluate whether sulodexide is safe and effective in treating
      subjects with type 2 diabetic nephropathy. Subjects with type 2 diabetes and microalbuminuria
      (defined as a urinary albumin to creatinine ratio,(ACR)in men 35-200 mg/G and in women 45-200
      mg/G) who are also receiving either irbesartan 300 mg/day, losartan 100 mg/day, or a maximum
      approved dose of an angiotensin receptor blocker (ARB) or angiotensin converting enzyme
      inhibitor (ACEI) will be enrolled in the study. The study will consist of the following
      periods:

        -  Screening: of 1-2 weeks for assessing basic eligibility/exclusion criteria

        -  Run-in: of up to 16 weeks on maximal dose of ARB or ACE with stable blood pressure
           control

        -  Qualifying visit: qualifying patients are on maximal dose of ARB or ACE for a minimum of
           4 months with stable BP control, SBP &lt;150 mmHg, DBP &lt;90 mmHg and albumin to creatinine
           ratio, (ACR) between in men 35-200 mg/G and in women 45-200 average of 3 first morning
           voids

        -  Randomization: patients are randomized to sulodexide 100 mg or matching placebo
           administered orally twice a day.

        -  Maintenance: 26 week maintenance period, with 4 visits to monitor safety and ACR

        -  Washout Period: 8 week washout period, with 2 visits to monitor safety and ACR
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Conversion From Microalbuminuria to Normoalbuminuria</measure>
    <time_frame>26 Weeks</time_frame>
    <description>The primary efficacy variable was the fraction of those patients in the ITT population with valid baseline and Week 26 ACRs in whom &quot;therapeutic success&quot; was achieved at Week 26 measured as a conversion of microalbuminuria to normoalbuminuria and at least a 25% reduction in ACR relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Greater Than 50% Reduction in Microalbuminuria</measure>
    <time_frame>26 Weeks</time_frame>
    <description>During the treatment period, KRX-101 is being compared to placebo to assess whether a 50% reduction in microalbuminuria has been achieved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Albumin From Baseline to End of 26 Weeks</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1056</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>Sulodexide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Also known as KRX-101. All patients will be on standard of care ACE or ARBs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All patients will be on standard of care ACE or ARBs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulodexide</intervention_name>
    <description>100 mg sulodexide gelcaps</description>
    <arm_group_label>Sulodexide</arm_group_label>
    <other_name>KRX-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mg gelcap</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo oral gelcap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes

          -  Serum creatinine equal to or less than 1.5 mg/dL

          -  Microalbuminuria, defined by a urine albumin/creatinine ratio in men; 35- 200 mg
             albumin/G creatinine, in women; 45-200 mg albumin/G creatinine

          -  Blood pressure controlled to less than 150/90 mmHg

          -  Willing to change antihypertensive medication regimen if necessary

        Exclusion Criteria:

          -  Age of onset of type 2 diabetes &lt;18 years;

          -  HbA1C &gt;10.0%;

          -  Morbid obesity defined as a body mass index (BMI) &gt;= 45 kg/m2;

          -  Type 1 (insulin-dependent; juvenile onset) diabetes;

          -  Renal disease as follows:

               -  Patients with known non-diabetic renal disease

               -  Renal allograft

          -  Absolute requirement for combination therapy of angiotensin converting enzyme
             inhibitors (ACEI) and angiotensin receptor blockers (ARB);

          -  Cardiovascular disease as follows:

               -  Unstable angina pectoris within 3 months of study entry;

               -  Myocardial infarction, coronary artery bypass graft surgery, or percutaneous
                  transluminal coronary angioplasty or stent placement within 3 months of study
                  entry;

               -  Transient ischemic attack within 3 months of study entry;

               -  Cerebrovascular accident within 3 months of study entry;

               -  Symptomatic heart failure requiring ACE inhibition;

               -  New York Heart Association Functional Class III or IV heart failure;

               -  Obstructive valvular heart disease or hypertrophic cardiomyopathy;

               -  Second or third degree atrioventricular block not successfully treated with a
                  pacemaker

          -  Need for chronic (&gt;2 weeks) immunosuppressive therapy, including corticosteroids
             (excluding inhaled or nasal steroids);

          -  History of multiple drug allergies;

          -  New diagnosis of cancer or recurrent cancer within 5 years of screening ( (except
             non-melanoma skin cancer);

          -  Psychiatric disorder that interferes with the patient's ability to comply with the
             protocol;

          -  Inability to tolerate oral medication or a history of significant malabsorption;

          -  Inability to remain on a stable dose of the following class of medications 30 days
             prior to randomization and throughout the study:

               -  3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins);

               -  Peroxisome proliferator-activated receptor gamma (PPAR gamma inhibitors
                  (glitazones);

               -  Cyclooxygenase-2 inhibitors (COX-2 inhibitors); or

               -  Non-steroidal anti-inflammatory drugs (NSAIDS);

          -  History of alcohol or other drug abuse within 12 months of study entry;

          -  Known human immunodeficiency virus (HIV) disease;

          -  Any other medical condition which renders the patient unable to or unlikely to
             complete the study, or which would interfere with optimal participation in the study
             or produce significant risk to the patient;

          -  Receipt of any investigational drugs (including placebo) within 30 days of enrollment;

          -  Evidence of hepatic dysfunction including total bilirubin &gt;2.0 mg/dL or liver
             transaminase (AST or ALT) &gt;3 times upper limit of normal;

          -  Anticipated surgery within trial period;

          -  Inability to cooperate with study personnel or history of noncompliance to medical
             regimen (i.e., patients who would be expected to comply poorly with treatment);

          -  Known allergies or intolerance to any heparin-like compound;

          -  Untreated urinary tract infection that would impact urinary protein values; or

          -  Prior exposure to sulodexide, either in a clinical setting or as a participant in
             another clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edmund J Lewis, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Collaborative Study Group, Rush University Medical Center, Chicago, IL USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert C Atkins, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Collaborative Study Group, Monash Medical Center, Clayton, Victoria, AUSTRALIA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dick deZeeuw, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Collaborative Study Group, University of Groningen, NETHERLANDS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Itamar Raz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Collaborative Study Group, Hadassah University, Jerusalem, ISRAEL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Collaborative Study Group, Clinical Coordinating Center for U.S. and Canadian Clinics, Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Collaborative Study Group, Clinical Coordinating Center for the Pacific Region, Monash Medical Center</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Collaborative Study Group, Clinical Coordinating Center for European Clinics, University of Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 AV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2005</study_first_submitted>
  <study_first_submitted_qc>August 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2005</study_first_posted>
  <results_first_submitted>January 23, 2018</results_first_submitted>
  <results_first_submitted_qc>February 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2018</results_first_posted>
  <disposition_first_submitted>April 13, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 13, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 5, 2015</disposition_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Albuminuria</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sulodexide</title>
          <description>Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
Sulodexide: 100 mg sulodexide gelcaps</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>All patients will be on standard of care ACE or ARBs.
Placebo: 0 mg gelcap</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Maintenance Period (26 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="524"/>
                <participants group_id="P2" count="532"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Valid Albumin Creatinine Ratio</title>
              <participants_list>
                <participants group_id="P1" count="492"/>
                <participants group_id="P2" count="494"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="502"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="502"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="494"/>
                <participants group_id="P2" count="490"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sulodexide</title>
          <description>Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
Sulodexide: 100 mg sulodexide gelcaps</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>All patients will be on standard of care ACE or ARBs.
Placebo: 0 mg gelcap</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="524"/>
            <count group_id="B2" value="532"/>
            <count group_id="B3" value="1056"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.0" spread="9.73"/>
                    <measurement group_id="B2" value="62.3" spread="9.90"/>
                    <measurement group_id="B3" value="62.2" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="394"/>
                    <measurement group_id="B2" value="408"/>
                    <measurement group_id="B3" value="802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="496"/>
                    <measurement group_id="B2" value="501"/>
                    <measurement group_id="B3" value="997"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="440"/>
                    <measurement group_id="B2" value="451"/>
                    <measurement group_id="B3" value="891"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Conversion From Microalbuminuria to Normoalbuminuria</title>
        <description>The primary efficacy variable was the fraction of those patients in the ITT population with valid baseline and Week 26 ACRs in whom “therapeutic success” was achieved at Week 26 measured as a conversion of microalbuminuria to normoalbuminuria and at least a 25% reduction in ACR relative to baseline</description>
        <time_frame>26 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulodexide</title>
            <description>Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
Sulodexide: 100 mg sulodexide gelcaps</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients will be on standard of care ACE or ARBs.
Placebo: 0 mg gelcap</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Conversion From Microalbuminuria to Normoalbuminuria</title>
          <description>The primary efficacy variable was the fraction of those patients in the ITT population with valid baseline and Week 26 ACRs in whom “therapeutic success” was achieved at Week 26 measured as a conversion of microalbuminuria to normoalbuminuria and at least a 25% reduction in ACR relative to baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Greater Than 50% Reduction in Microalbuminuria</title>
        <description>During the treatment period, KRX-101 is being compared to placebo to assess whether a 50% reduction in microalbuminuria has been achieved.</description>
        <time_frame>26 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulodexide</title>
            <description>Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
Sulodexide: 100 mg sulodexide gelcaps</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients will be on standard of care ACE or ARBs.
Placebo: 0 mg gelcap</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Greater Than 50% Reduction in Microalbuminuria</title>
          <description>During the treatment period, KRX-101 is being compared to placebo to assess whether a 50% reduction in microalbuminuria has been achieved.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Albumin From Baseline to End of 26 Weeks</title>
        <time_frame>26 Weeks</time_frame>
        <population>Participant numbers include those with both baseline and week 26 measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Sulodexide</title>
            <description>Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
Sulodexide: 100 mg sulodexide gelcaps</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All patients will be on standard of care ACE or ARBs.
Placebo: 0 mg gelcap</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Albumin From Baseline to End of 26 Weeks</title>
          <population>Participant numbers include those with both baseline and week 26 measurements</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
                <count group_id="O2" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.01"/>
                    <measurement group_id="O2" value="-0.02" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for the full duration of the trial (34 weeks)</time_frame>
      <desc>The safety population consisted of all patients who were administered at least 1 dose of study medication. There was one patient in the sulodexide group who was randomized but did not receive study medication</desc>
      <group_list>
        <group group_id="E1">
          <title>Sulodexide</title>
          <description>Also known as KRX-101. All patients will be on standard of care ACE or ARBs.
Sulodexide: 100 mg sulodexide gelcaps</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>All patients will be on standard of care ACE or ARBs.
Placebo: 0 mg gelcap</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Post-procedural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Ischaemic Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Sigmoiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Device Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Spinal Cord Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Colon Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Non-Hodgkins Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Bladder Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Hemorhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Obstructive Airways Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Sleep Apnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="348" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="358" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac Murmur</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Pain in extremities</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Hypoesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="532"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="523"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="532"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Keryx Biopharmaceuticals</organization>
      <phone>1-844-44-KERYX</phone>
      <email>medicalinfo@keryx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

